fostamatinib

a spleen tyrosine kinase (Syk) inhibitor, metabolized to R406

Also Known As:

(6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-pyrido(3,2-b)-1,4-oxazin-4-yl)methyl disodium phosphate hexahydrate; 2H-pyrido(3,2-b)-1,4-oxazin-3(4H)-one, 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)-4-pyrimidinyl)amino)-2,2-dimethyl-4-((phosphonooxy)methyl)-; 2H-pyrido(3,2-b)-1,4-oxazin-3(4H)-one, 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)-4-pyrimidinyl)amino)-2,2-dimethyl-4-((phosphonooxy)methyl)-, sodium salt (1:2); R-788 free acid; R-788 sodium; R-788 sodium anhydrous; R-788 sodium hydrate; R-935788 free acid; R-935788 sodium anhydrous; R-935788 sodium hydrate; R788 free acid; R788 sodium; R788 sodium anhydrous; R788 sodium hydrate; R935788 free acid; R935788 sodium anhydrous; R935788 sodium hydrate; Tavalisse; fostamatinib disodium; fostamatinib disodium anhydrous; fostamatinib disodium hydrate; fostamatinib disodium salt hexahydrate

Networked: 143 relevant articles (22 outcomes, 39 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	McAdoo, Stephen P: 6 articles (10/2021 - 01/2011)
2.	Tam, Frederick W K: 6 articles (11/2020 - 02/2010)
3.	Weinblatt, Michael E: 6 articles (01/2018 - 02/2011)
4.	Cooper, Nichola: 5 articles (04/2021 - 01/2018)
5.	Bussel, James B: 5 articles (01/2021 - 01/2018)
6.	Ho, Meilien: 5 articles (09/2017 - 12/2014)
7.	Genovese, Mark C: 5 articles (12/2015 - 02/2011)
8.	Braddock, Martin: 4 articles (01/2018 - 01/2015)
9.	Kavanaugh, Arthur: 4 articles (12/2014 - 02/2011)
10.	Grossbard, Elliott B: 4 articles (07/2013 - 02/2011)

Related Diseases

1.	Rheumatoid Arthritis 01/01/2019 - "Conclusions: Fostamatinib is an effective and safe therapeutic medicine administered to patients with rheumatoid arthritis over 24 weeks. " 03/01/2015 - "This analysis aimed at developing a pharmacodynamic model for efficacy using pooled ACR20 data from two phase II studies in patients with rheumatoid arthritis (TASKi1 and TASKi2), describing the effect of fostamatinib as a function of fostamatinib exposure (dose, R406 plasma concentration) and other explanatory variables. " 11/01/2014 - "The OSKIRA-ambulatory BP monitoring trial assessed the effect of fostamatinib on 24-hour ambulatory systolic BP (SBP) in patients with active rheumatoid arthritis. " 11/01/2014 - "Clinical trials of fostamatinib in patients with rheumatoid arthritis showed blood pressure (BP) elevation using clinic measurements. " 01/01/2021 - "Objective: This systematic review and meta-analysis is aimed at assessing the risks of cardiovascular adverse events in patients with rheumatoid arthritis (RA) who have been treated with fostamatinib. "
2.	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 11/01/2019 - "Fostamatinib disodium hexahydrate: a novel treatment for adult immune thrombocytopenia." 12/01/2020 - "Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia." 01/01/2023 - "Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study." 01/01/2018 - "Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials." 09/29/2023 - "Fostamatinib or Thrombopoietic Receptor Agonists for the Treatment of Chronic Immune Thrombocytopenia in Adult Patients: A Real-World Assessment of Safety, Effectiveness and Cost."
3.	COVID-19 01/01/2022 - "For COVID-19 requiring hospitalization, the addition of fostamatinib to standard of care was safe and patients were observed to have improved clinical outcomes compared with placebo. " 01/01/2022 - "Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial." 01/01/2022 - "Our computational study and docking results suggest that Fostamatinib (R406 as its active promoiety) may also be considered as one of the potential candidates for further clinical trials in pursuit to counter the spread of COVID-19." 06/01/2023 - "A remarkable example is Fostamatinib that has been shown to lower mortality, shorten the length of ICU stay, and reduce disease severity of hospitalized Covid-19 patients. " 01/01/2022 - "Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/R406 a potential candidate?"
4.	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 02/01/2016 - "A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)." 02/01/2016 - "To assess the safety and efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). " 01/01/2010 - "The mTOR inhibitors temsirolimus and everolimus have demonstrated antitumor activity in all types of lymphoma, the Syk inhibitor fostamatinib has activity in diffuse large B-cell lymphoma and chronic lymphocytic leukemia, and the PKC-β inhibitor enzastaurin is being used as consolidation therapy after remission in diffuse large B-cell lymphoma. "
5.	Inflammation (Inflammations) 12/01/2023 - "Researchers are also currently investigating the use of drugs that inhibit SYK, including fostamatinib, for the potential treatment of other diseases associated with inflammation (e.g. " 01/01/2015 - "Fostamatinib, a small molecule SYK inhibitor, has shown evidence of ameliorating inflammation in RA patients. " 07/01/2015 - "Mice treated with fostamatinib also displayed less fibrosis and inflammation in the lung tissue. " 01/01/2023 - "The use of the oral Spleen tyrosine Kinase inhibitor Fostamatinib significantly reduced expression of genes associated with chronic inflammation, fibroblast proliferation and migration suggesting a potential role for targeting fibroblast activity in HS." 01/01/2022 - "To inhibit and validate these targets, we tested fostamatinib (targeting SYK) and Gefitinib (targeting EGFR), and both drugs effectively ameliorated pulmonary dysfunction and inhibited the progression of inflammation and fibrosis. "

Related Drugs and Biologics

1.	Inosine Triphosphate (ITP)
2.	Methotrexate (Mexate)
3.	Rituximab (Mabthera)
4.	Syk Kinase
5.	Biomarkers (Surrogate Marker)
6.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
7.	Prodrugs
8.	Collagen
9.	Collagen Type I (Type I Collagen)
10.	Matrix Metalloproteinases (MMPs)

Related Therapies and Procedures

1.	Therapeutics
2.	Splenectomy
3.	Length of Stay
4.	Heterologous Transplantation (Xenotransplantation)
5.	Biological Therapy